[Molecular targets in colon cancer]

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Colorectal cancer is a significant cause of cancer mortality in Switzerland.
• Historically, treatment options were limited, but recent therapeutic advances have emerged.
• New chemotherapy drugs (irinotecan, oxaliplatin) and molecular targeted therapies have transformed treatment.

Purpose of the Study:

• To review molecular targets currently under active clinical investigation for colon cancer.
• To highlight the shift from traditional chemotherapy to targeted molecular therapies.
• To discuss the therapeutic potential of inhibiting specific cellular pathways in colon cancer.

Main Methods:

• Review of recent clinical investigations and therapeutic advances in colorectal cancer.
• Focus on molecular targeted therapies and their mechanisms of action.
• Analysis of pathways such as epidermal growth factor receptor and angiogenesis.

Main Results:

• Molecular targeted therapies have shown significant promise in treating colorectal cancer.
• Inhibition of the epidermal growth factor receptor (EGFR) demonstrates therapeutic potential.
• Targeting angiogenesis, particularly the vascular endothelial growth factor (VEGF) pathway, is a successful strategy.

Conclusions:

• Molecular targeted therapy represents a paradigm shift in colorectal cancer treatment.
• Targeting specific cellular pathways offers a favorable therapeutic index.
• Ongoing clinical investigations continue to identify and validate new molecular targets for colon cancer.